182 related articles for article (PubMed ID: 30449600)
1. Inhibition of Drp1 hyperactivation reduces neuropathology and behavioral deficits in zQ175 knock-in mouse model of Huntington's disease.
Zhao Y; Sun X; Qi X
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):319-323. PubMed ID: 30449600
[TBL] [Abstract][Full Text] [Related]
2. Drp1/Fis1-mediated mitochondrial fragmentation leads to lysosomal dysfunction in cardiac models of Huntington's disease.
Joshi AU; Ebert AE; Haileselassie B; Mochly-Rosen D
J Mol Cell Cardiol; 2019 Feb; 127():125-133. PubMed ID: 30550751
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration.
Guo X; Disatnik MH; Monbureau M; Shamloo M; Mochly-Rosen D; Qi X
J Clin Invest; 2013 Dec; 123(12):5371-88. PubMed ID: 24231356
[TBL] [Abstract][Full Text] [Related]
4. Drp1 phosphorylation by MAPK1 causes mitochondrial dysfunction in cell culture model of Huntington's disease.
Roe AJ; Qi X
Biochem Biophys Res Commun; 2018 Feb; 496(2):706-711. PubMed ID: 29397067
[TBL] [Abstract][Full Text] [Related]
5. S-nitrosylation of dynamin-related protein 1 mediates mutant huntingtin-induced mitochondrial fragmentation and neuronal injury in Huntington's disease.
Haun F; Nakamura T; Shiu AD; Cho DH; Tsunemi T; Holland EA; La Spada AR; Lipton SA
Antioxid Redox Signal; 2013 Oct; 19(11):1173-84. PubMed ID: 23641925
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Behavioral, Neuropathological, Brain Metabolic and Key Molecular Changes in zQ175 Knock-In Mouse Model of Huntington's Disease.
Peng Q; Wu B; Jiang M; Jin J; Hou Z; Zheng J; Zhang J; Duan W
PLoS One; 2016; 11(2):e0148839. PubMed ID: 26859386
[TBL] [Abstract][Full Text] [Related]
7. Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease.
Heikkinen T; Lehtimäki K; Vartiainen N; Puoliväli J; Hendricks SJ; Glaser JR; Bradaia A; Wadel K; Touller C; Kontkanen O; Yrjänheikki JM; Buisson B; Howland D; Beaumont V; Munoz-Sanjuan I; Park LC
PLoS One; 2012; 7(12):e50717. PubMed ID: 23284644
[TBL] [Abstract][Full Text] [Related]
8. VGLUT3 Deletion Rescues Motor Deficits and Neuronal Loss in the zQ175 Mouse Model of Huntington's Disease.
Ibrahim KS; El Mestikawy S; Abd-Elrahman KS; Ferguson SSG
J Neurosci; 2023 Jun; 43(23):4365-4377. PubMed ID: 37055181
[TBL] [Abstract][Full Text] [Related]
9. Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease.
Ma Q; Yang J; Li T; Milner TA; Hempstead BL
Neurobiol Dis; 2015 Oct; 82():466-477. PubMed ID: 26282324
[TBL] [Abstract][Full Text] [Related]
10. Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease.
Jin J; Peng Q; Hou Z; Jiang M; Wang X; Langseth AJ; Tao M; Barker PB; Mori S; Bergles DE; Ross CA; Detloff PJ; Zhang J; Duan W
Hum Mol Genet; 2015 May; 24(9):2508-27. PubMed ID: 25609071
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial cristae remodelling is associated with disrupted OPA1 oligomerisation in the Huntington's disease R6/2 fragment model.
Hering T; Kojer K; Birth N; Hallitsch J; Taanman JW; Orth M
Exp Neurol; 2017 Feb; 288():167-175. PubMed ID: 27889468
[TBL] [Abstract][Full Text] [Related]
12. Increased mitochondrial fission and neuronal dysfunction in Huntington's disease: implications for molecular inhibitors of excessive mitochondrial fission.
Reddy PH
Drug Discov Today; 2014 Jul; 19(7):951-5. PubMed ID: 24681059
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Drp1 mitochondrial translocation provides neural protection in dopaminergic system in a Parkinson's disease model induced by MPTP.
Filichia E; Hoffer B; Qi X; Luo Y
Sci Rep; 2016 Sep; 6():32656. PubMed ID: 27619562
[TBL] [Abstract][Full Text] [Related]
14. Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease.
Menalled LB; Kudwa AE; Oakeshott S; Farrar A; Paterson N; Filippov I; Miller S; Kwan M; Olsen M; Beltran J; Torello J; Fitzpatrick J; Mushlin R; Cox K; McConnell K; Mazzella M; He D; Osborne GF; Al-Nackkash R; Bates GP; Tuunanen P; Lehtimaki K; Brunner D; Ghavami A; Ramboz S; Park L; Macdonald D; Munoz-Sanjuan I; Howland D
PLoS One; 2014; 9(6):e99520. PubMed ID: 24955833
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Electroencephalographic Analysis Provides an Early-Stage Indicator of Disease Onset and Progression in the zQ175 Knock-In Mouse Model of Huntington's Disease.
Fisher SP; Schwartz MD; Wurts-Black S; Thomas AM; Chen TM; Miller MA; Palmerston JB; Kilduff TS; Morairty SR
Sleep; 2016 Feb; 39(2):379-91. PubMed ID: 26446107
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175.
Menalled LB; Kudwa AE; Miller S; Fitzpatrick J; Watson-Johnson J; Keating N; Ruiz M; Mushlin R; Alosio W; McConnell K; Connor D; Murphy C; Oakeshott S; Kwan M; Beltran J; Ghavami A; Brunner D; Park LC; Ramboz S; Howland D
PLoS One; 2012; 7(12):e49838. PubMed ID: 23284626
[TBL] [Abstract][Full Text] [Related]
17. Cognitive deficits in transgenic and knock-in HTT mice parallel those in Huntington's disease.
Farrar AM; Murphy CA; Paterson NE; Oakeshott S; He D; Alosio W; McConnell K; Menalled LB; Ramboz S; Park LC; Howland D; Brunner D
J Huntingtons Dis; 2014; 3(2):145-58. PubMed ID: 25062858
[TBL] [Abstract][Full Text] [Related]
18. ATAD3A oligomerization causes neurodegeneration by coupling mitochondrial fragmentation and bioenergetics defects.
Zhao Y; Sun X; Hu D; Prosdocimo DA; Hoppel C; Jain MK; Ramachandran R; Qi X
Nat Commun; 2019 Mar; 10(1):1371. PubMed ID: 30914652
[TBL] [Abstract][Full Text] [Related]
19. Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease.
Hickey MA; Zhu C; Medvedeva V; Lerner RP; Patassini S; Franich NR; Maiti P; Frautschy SA; Zeitlin S; Levine MS; Chesselet MF
Mol Neurodegener; 2012 Apr; 7():12. PubMed ID: 22475209
[TBL] [Abstract][Full Text] [Related]
20. Metabotropic Glutamate Receptor 2/3 Activation Improves Motor Performance and Reduces Pathology in Heterozygous zQ175 Huntington Disease Mice.
Li SH; Colson TL; Abd-Elrahman KS; Ferguson SSG
J Pharmacol Exp Ther; 2021 Oct; 379(1):74-84. PubMed ID: 34330748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
